CDKN2A and cancer: Among these potential druggable alterations, EGFR, KRAS, and PIK3CA gene alterations were the most common, while CDK pathway (CDK4/6, CDKN2A/2B), FGFR1/2/3, BRAF, RET was uncommon across pan-cancer.